RNA processing as an alternative route to attack glioblastoma

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Glioblastoma (GBM) is a highly malignant brain tumor with poor patient survival and limited therapeutic options.
• Genomic analyses of GBM, including TCGA data, have identified key alterations but have not yet led to improved clinical outcomes.
• Alternative splicing is a major source of transcript variation, implicated in cancer development and progression.

Purpose of the Study:

• To review the current literature on RNA processing in glioblastoma.
• To present a case for exploring RNA processing as a therapeutic strategy for GBM.
• To highlight the role of alternative splicing in cancer-specific isoforms and pathways.

Main Methods:

• Literature review of genomic and transcriptomic analyses in GBM.
• Examination of the role of alternative splicing in cancer-critical pathways.
• Discussion of the targetability of splicing machinery components.

Main Results:

• Alternative splicing affects over 90% of human coding genes and generates cancer-specific isoforms.
• Splicing defects can drive tumor evolution, genomic instability, and affect pathways like apoptosis and cell proliferation.
• Components of the splicing machinery are targetable with existing or developing drugs.

Conclusions:

• Alternative splicing represents a significant, yet underexplored, regulatory route in GBM.
• Targeting RNA processing offers a novel therapeutic avenue for glioblastoma treatment.
• Exploiting splicing alterations could potentially improve clinical outcomes for GBM patients.